These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11138404)

  • 1. [Evaluation of the risk of osteoporosis in postmenopausal patients in the Hospital Luis Castelazo Ayala of the Mexican Social Security Institute, using a risk factor questionnaire].
    Mac Gregor Gooch AL; García López F; Carranza Lira S
    Ginecol Obstet Mex; 2000 Oct; 68():425-8. PubMed ID: 11138404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology, etiology, and diagnosis of osteoporosis.
    Lane NE
    Am J Obstet Gynecol; 2006 Feb; 194(2 Suppl):S3-11. PubMed ID: 16448873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoporosis in postmenopausal women (Mexico City): 1. Risk factors.
    Carranza-Lira S; Rosas M; Murillo A; Martínez N; Santos J
    Int J Fertil Womens Med; 2002; 47(1):22-5. PubMed ID: 11900271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New possibilities for diagnosis and treatment of osteoporosis.
    Miller PD
    Int J Fertil Womens Med; 2001; 46(4):215-21. PubMed ID: 11563832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term estrogen and hormone replacement therapy for the prevention and treatment of osteoporosis.
    Levine JP
    Curr Womens Health Rep; 2003 Jun; 3(3):181-6. PubMed ID: 12734027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
    Barrett-Connor E; Wehren LE; Siris ES; Miller P; Chen YT; Abbott TA; Berger ML; Santora AC; Sherwood LM
    Menopause; 2003; 10(5):412-9. PubMed ID: 14501602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A
    Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk factors for osteoporosis in women having hip fractures after 60 years of age].
    Unay K; Demirçay E; Akan K; Sener N
    Acta Orthop Traumatol Turc; 2005; 39(4):295-9. PubMed ID: 16269875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of lifestyle and risk factors on bone mineral density in a cohort of Italian women: suggestion for a new decision rule.
    D'Amelio P; Tamone C; Pluviano F; Di Stefano M; Isaia G
    Calcif Tissue Int; 2005 Aug; 77(2):72-8. PubMed ID: 16059776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmenopausal osteoporosis and hormone replacement therapy.
    Gambacciani M; Vacca F
    Minerva Med; 2004 Dec; 95(6):507-20. PubMed ID: 15785435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for osteoporosis and bone status in postmenopausal women with psoriasis treated with UVB therapy.
    Osmancevic A; Landin-Wilhelmsen K; Larkö O; Mellström D; Wennberg AM; Hulthén L; Krogstad AL
    Acta Derm Venereol; 2008; 88(3):240-6. PubMed ID: 18480922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoporosis and cardiovascular disease: benefit-risk of hormone replacement therapy.
    Sammartino A; Cirillo D; Mandato VD; Di Carlo C; Nappi C
    J Endocrinol Invest; 2005; 28(10 Suppl):80-4. PubMed ID: 16550729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for clinical fractures among postmenopausal women: a 10-year prospective study.
    van Geel TA; Geusens PP; Nagtzaam IF; van der Voort DJ; Schreurs CM; Rinkens PE; Dinant GJ
    Menopause Int; 2007 Sep; 13(3):110-5. PubMed ID: 17785036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Postmenopausal osteoporosis].
    László A
    Orv Hetil; 2004 Jan; 145(1):3-13. PubMed ID: 15222134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical risk factors for fracture in postmenopausal osteoporotic women: a review of the recent literature.
    LaFleur J; McAdam-Marx C; Kirkness C; Brixner DI
    Ann Pharmacother; 2008 Mar; 42(3):375-86. PubMed ID: 18230704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiologic and economic considerations of osteoporosis.
    Caldwell JR
    J Fla Med Assoc; 1996 Oct; 83(8):548-51. PubMed ID: 9159999
    [No Abstract]   [Full Text] [Related]  

  • 19. Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry.
    Sedrine WB; Chevallier T; Zegels B; Kvasz A; Micheletti MC; Gelas B; Reginster JY
    Gynecol Endocrinol; 2002 Jun; 16(3):245-50. PubMed ID: 12192897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of osteoporosis-related hip fractures using hospital discharge data.
    Rubin BR; René AA; Mains DA; Marshall MA
    J Am Osteopath Assoc; 2003 Apr; 103(4):169-75. PubMed ID: 12733546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.